Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies

Jutta Stoffers-Winterling*, Ole Jakob Storebø, Klaus Lieb

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

123 Downloads (Pure)


Purpose of the Review: We aim to identify the most recent evidence of randomised controlled trials evaluating continued drug treatments in people with a diagnosis of BPD, review the most recent findings, highlight trends in terms of currently ongoing studies and comment on the overall body of evidence. Recent Findings: We identified seven new RCTs, plus newly available data for an older RCT. Only three of these RCTs have been published in full text, while we found study data posted at trial registry platforms for the others. Summary: The new findings do not support fluoxetine as a treatment option for suicide and self-harm prevention. A large effectiveness study did not detect beneficial effects of lamotrigine in routine care. The prevalent use of medications in BPD is still not reflected or supported by the current evidence. More research is needed regarding the most commonly used substances and substance classes, i.e. SSRIs, and quetiapine, but also with respect to people presenting with distinct comorbid conditions.

Original languageEnglish
Article number37
JournalCurrent Psychiatry Reports
Issue number8
Number of pages10
Publication statusPublished - 1. Aug 2020


  • Anticonvulsants
  • Antidepressants
  • Antipsychotics
  • Borderline personality disorder
  • Drug treatment
  • Review
  • Humans
  • Suicide
  • Randomized Controlled Trials as Topic
  • Self-Injurious Behavior
  • Borderline Personality Disorder/drug therapy
  • Lamotrigine
  • Serotonin Uptake Inhibitors


Dive into the research topics of 'Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies'. Together they form a unique fingerprint.

Cite this